Immunology Biopharmaceutical

Biopharmaceuticals
Biotech
COVID-19
Dividend Stocks
Dividends
Fibonacci Retracement
Fundamental Analysis
Immunology Biopharmaceutical
InvestivDaily
Large Cap
Pharmaceuticals
Technical Analysis
Vaccines
Value Investing

JNJ is stabilizing after dropping off a 52-week high – is it a good buy?

Years ago, as I began my career as an investor, I read a book by Peter Lynch. Mr. Lynch had made his name, and his fortune, as the manager of Fidelity’s flagship Magellan fund in the late 70’s and ’80’s, and his incredible performance was one of the big reasons Magellan, at the time, was […]

Read More
Biotech
Cancer
Cancer Biopharmaceuticals
Coronavirus
COVID-19
Dividends
Economy
Fibonacci Retracement
Fundamental Analysis
HeathCare
Immunology Biopharmaceutical
Immunotherapies
InvestivDaily
Pharmaceuticals
RNA Biotechnology
Technical Analysis
Tumor-Specific Cancer Immunotherapies
Vaccines
Value Investing

PFE is down about 20% in the last three months, and that’s a good thing for value-focused investors

As recently as a few months ago, a lot of signs about the global pandemic seemed to suggest that the worst of the worst was over, and we could all finally begin to put COVID-19 concerns and commentary in the rear view. As contagious variants of the virus have emerged, however, it has become more […]

Read More
Automotive Retail
Daily Rundown
Digital Media
Genetically Defined Diseases
Immunology Biopharmaceutical
Property and Casualty Reinsurance

Genetically Defined Diseases, Digital Media, Property and Casualty Reinsurance, Automotive Retail, Immunology Biopharmaceutical

Fulcrum Therapeutics, Inc. (FULC) Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule that is in Phase 2b clinical trial for the treatment […]

Read More
X